Translational Cardiovascular Therapeutics

Abstract

Cardiovascular disease remains the leading cause of mortality in Europe, driving substantial translational research investment from mechanistic discovery through clinical deployment. The past decade has produced multiple therapeutic classes -- PCSK9 inhibitors, sacubitril/valsartan, SGLT2 inhibitors, icosapent ethyl, vericiguat, and emerging small interfering RNA agents -- that have transformed management of lipid disorders, heart failure, and cardiometabolic risk. The efficiency of their translational pathways has varied enormously, with some reaching guideline recommendation within 3-4 years of pivotal trial readout while others have languished in post-trial regulatory and implementation phases for a decade or more. Understanding which translational models consistently deliver cardiovascular therapeutic advances to patients efficiently is essential for prioritising future research investment. We evaluated five translational therapeutic pathway models across 186 cardiovascular therapeutic development programmes at 24 European academic and industry sites between 2012 and 2024. Frameworks ranged from conventional industry-led drug development through fully integrated academic-industry-patient-regulatory translational consortia. Performance was benchmarked using our Cardiovascular Translational Efficiency Score (CTES), integrating time-to-guideline-recommendation, clinical outcome magnitude, implementation uptake rate, health equity impact, and scientific reproducibility. The integrated consortium framework achieved the highest CTES (0.921), reducing time from pivotal trial readout to ESC guideline incorporation from 4.8 years (industry-only) to 2.4 years, and accelerating real-world uptake to 68.4% of eligible patients within 3 years versus 34.2% for industry-only pathways. SGLT2 inhibitor and sacubitril/valsartan pathways exemplified efficient consortium translation, while PCSK9 inhibitors remain under-implemented despite strong efficacy evidence, highlighting reimbursement and patient access as the residual translational bottleneck.